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Introduction
Deficiency of interleukin-1-receptor antagonist (DIRA) is
a rare autoinflammatory disease clinically characterized
by early-onset generalized pustulosis, multifocal osteo-
myelitis and elevation of acute-phase reactants. DIRA is
caused by autosomal recessive loss of function mutations
in IL1RN. Seven DIRA causing mutations have been
described, including one 175Kb genomic deletion, 4 pre-
mature stopcodons, 1 inframe deletion, and 1 missense
mutation.
Objective
To report a novel disease-causing deletion affecting
IL1RN gene in an Indian patient with DIRA.
Methods
The patient was enrolled into a NIH natural history proto-
col. Peripheral blood genomic DNA was obtained and
patient was genotyped for the detection of copy number
variations (CNVs) by a SNP array technique. As deter-
mined by SNP array, primers flanking the deletion ends
were designed and the breakpoint area was amplified by
polymerase chain reaction (PCR) and sequenced by Sanger
technique.
Results
Clinical description: A 5 month-old Indian girl, born to
healthy non-consanguineous parents presented with
pain on manipulation and irritability at the 3rd week of
life and developed a mild pustular rash limited to the
back of neck and upper forehead. Bone scintigraphy
suggested osteomyelitis of multiple bones, including
ribs, clavicles and long bones and cultures from left
wrist bone biopsy material were negative. Primary
immunodeficiency work up was negative. There was no
clinical response to a 5-week course of broad-spectrum
antibiotics, and thus an autoinflammatory condition was
suspected. Prednisolone was initiated and the patient
had significant clinical improvement. Due to a clinical
suspicion of DIRA, the patient was enrolled in a NIH
protocol and started on recombinant interleukin-1
receptor antagonist (anakinra). Anakinra initiation
resulted in marked and sustained clinical and laboratory
improvement.
Genetic analysis: SNP array analysis of patient’s genomic
DNA showed loss of heterozygosity for all SNPs in a
region of approximately 21.4 to 23.7kb, indicating a homo-
zygous deletion. PCR and sequencing of the breakpoint
area allowed us to identify the breakpoints of the deletion,
at chr2_hg19_113,865,011 and chr2_hg19_113,887,227,
confirming a homozygous 22,216bp deletion that spans
the first four exons of IL1RN (NM_173843). This deletion
has not been previously reported in patients with DIRA.
Conclusion
We describe the first Indian patient with DIRA and a
novel homozygous 22Kb deletion spanning 2 coding
exons of IL1RN. The primers designed to detect the
novel deletion will be useful to screen Indian patients
with a clinical suspicion of DIRA.
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